NCT07285954 Mindfulness Walking Intervention to Enhance Resilience (iWalk)
| NCT ID | NCT07285954 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Urbana-Champaign |
| Condition | Neurodegenerative Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2025-06-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized controlled trial of the walking meditation intervention (iWalk) program, a multi-component intervention integrating walking meditation, education, and group sessions designed to enhance resilience in individuals with multiple sclerosis (MS). The objectives are to evaluate: 1. Recruitment capability and retention rates, 2. Acceptability and adherence to the intervention, 3. Feasibility of assessment procedures, and 4. Preliminary effects on psychological, physiological, and behavioral outcomes.
Eligibility Criteria
Inclusion Criteria: 1. 18 years or older, 2. clinical diagnosis of a neurodegenerative disease such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, etc., 3. have not practiced meditation regularly (e.g., 10 mins per day) and have never attended any meditation classes or community programs, 4. never received meditation training via coaching/certification/life coaching, 5. have internet access, 6. with no severe cognitive impairment, i.e., have a score of ≥ 21 on Modified Telephonic Interview for Cognitive Status (TICS-M), 7. be able to walk with or without an assistive device (Patient determined Disease Steps score ranged from 0-6), 8. are willing to be randomized to an intervention or a control group, 9. are willing to wear Fitbit (a wrist smart watch) for eight weeks, 10. are individuals who are right-handed according to the Edinburgh Handedness Questionnaire, 11. are willing to participate in all assessments, including in-person testing using electroencephalography (EEG) and cognitive tests, online survey/questionnaires, and online interviews or focus group discussions, 12. are willing to wear a Hexoskin t-shirt, which is a heart rate variability monitor, while doing the assessments in person. Exclusion Criteria: Participants who cannot speak, read, write, or listen in English.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07285954 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Neurodegenerative Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07285954 currently recruiting?
Yes, NCT07285954 is actively recruiting participants. Contact the research team at chiucy@illinois.edu for enrollment information.
Where is the NCT07285954 trial being conducted?
This trial is being conducted at Urbana, United States.
Who is sponsoring the NCT07285954 clinical trial?
NCT07285954 is sponsored by University of Illinois at Urbana-Champaign. The trial plans to enroll 90 participants.